Evaluation of the Impact of the UPLUG Device Onto the Infection Rate of Indwelling Central Venous Catheters in Patients Undergoing Chronic Hemodialysis
NCT ID: NCT05670964
Last Updated: 2024-05-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
7 participants
INTERVENTIONAL
2023-10-16
2024-03-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
As it is a major concern for the medical community, this clinical investigation aims at assessing, in real world conditions, the impact of the UPLUG device onto the infection rate of indwelling central venous haemodialysis catheters.
UPLUG-EVIDENCE is an international, multicenter, randomised, open label trial that will evaluate the efficacy of the UPLUG device on the reduction of bacterial infections in patients undergoing chronic haemodialysis with central venous catheter (CVC).
The UPLUG device has been designed to :
1. reduce the haemodialysis catheter openings, hence potentially reducing the infectious risk,
2. improve the lock solution infusion using a positive pressure, limiting the thrombosis risk and associated haemodialysis catheter dysfunction
3. limit the time needed to connect and disconnect the patient, by facilitating how the different steps are operated, and even allowing a connection/disconnection with a single healthcare professional
4. ultimately enhance patient's autonomy with ergonomics \& safe procedures
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Catheter Dysfunction Rate in Patients Undergoing Kidney Replacement Therapy. Evaluation of the Safety and Efficacy of Anti-reflux Valves Without Heparin Lock Solution
NCT06259266
Feasibility and Evaluation Study of the UPLUG Hemodialysis Connection Device
NCT05419258
Hemodialysis in the Elderly (70yrs & Older)
NCT03065972
Improving the Outcomes of Peritoneal Dialysis (PD) Catheter Insertion
NCT04034628
Impact of Catheter Design on Catheter Survival in Chronic Hemodialysis Patients
NCT01649102
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The UPLUG device consists of 2 parts :
1. the UPLUG Port, a sterile, single use device connected to the distal Luer-Lock connectors of a regular central venous catheter. It may be connected up to 29 days and
2. the UPLUG Disposable, a sterile, single use device indicated for use with the UPLUG Port to perform a chronic haemodialysis therapy. it will be changed at every dialysis session.
Treatment period (16 weeks):
W1:D1 : first connection of the UPLUG Port The patient will be seen by a nurse or an investigator at D29, D57 and D85 for UPLUG port periodical replacement, and at D113 for the definitive withdrawal of the UPLUG port.
Follow-up period (29 days):
A last visit (onsite or call) is planned during the definitive withdrawal of the CVC or no later than 29 days after the end of the treatment period (D113) to assess the safety and well-being of the patient
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
UPLUG Arm
Patients will have regular central veinous catheter and UPLUG device for their dialysis sessions.
Connecting valve system
UPLUG Port (changed every 29 days) and UPLUG Disposable (changed at every dialysis session) ensure the connection between a regular haemodialysis catheter and an extracorporeal circuit, and proceed to different steps of haemodialysis session without handling the Luer-Lock connectors of the haemodialysis catheter
Central haemodialysis Venous Catheter
Central haemodialysis venous catheter (CE marked) will be used within the scope of their intended purpose during the dialysis session
Standard Of Care Arm
Patients will have regular central veinous catheter (standard of care) for their dialysis.
Central haemodialysis Venous Catheter
Central haemodialysis venous catheter (CE marked) will be used within the scope of their intended purpose during the dialysis session
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Connecting valve system
UPLUG Port (changed every 29 days) and UPLUG Disposable (changed at every dialysis session) ensure the connection between a regular haemodialysis catheter and an extracorporeal circuit, and proceed to different steps of haemodialysis session without handling the Luer-Lock connectors of the haemodialysis catheter
Central haemodialysis Venous Catheter
Central haemodialysis venous catheter (CE marked) will be used within the scope of their intended purpose during the dialysis session
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Chronic haemodialysis
* indwelling de novo or replacement central veinous catheter
Exclusion Criteria
* Renal transplantation already scheduled at inclusion (living donor)
* Current infection of CVC percutaneous or subcutaneous site
* Pregnant or breastfeeding female, or women without a medically significant contraceptive regimen
* Patient with mechanical heart valve
* Patient with an AVF likely to be functional within 1 month
* Strictly more than 3 dialysis sessions a week
* Patient undergoing haemodialysis session \> 4h30
* Participation to another clinical study in the last 30 days period
* Patient unable to give a freely-given, written, informed consent
* Vulnerable participants
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assistance Publique - Hôpitaux de Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hafedh FESSI, PH
Role: PRINCIPAL_INVESTIGATOR
Assistance Publique - Hôpitaux de Paris
Dominique JOLY, PUPH
Role: STUDY_DIRECTOR
Assistance Publique - Hôpitaux de Paris
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hôpital Tenon, service de Néphrologie
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
APHP211510
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.